Measuring joint involvement in polyarticular psoriatic arthritis: An introduction of alternatives

Arthritis Care and Research

Volumn 62, Issue 7, 2010, Pages 977-983

  Englbrecht, M ^a   Wang, Y ^b   Ronneberger, M ^a   Manger, B ^a   Vastesaeger, N ^b   Veale, D J ^c   Schett, G ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; PLACEBO;

ANKLE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELBOW; GOLD STANDARD; HUMAN; INTERPHALANGEAL JOINT; KNEE; MAJOR CLINICAL STUDY; PSORIATIC ARTHRITIS; RELIABILITY; SCORING SYSTEM; WRIST;

ARTHRALGIA; ARTHRITIS, PSORIATIC; HUMANS; LOGISTIC MODELS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 77954272410     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20161     Document Type: Article

References (34)

1. Veale DJ, FitzGerald O. Psoriatic arthritis: pathogenesis and epidemiology. Clin Exp Rheumatol 2002;20 Suppl 28:S27-33.
2. Barton AC. Genetic epidemiology: psoriatic arthritis. Arthritis Res 2002;4:247-51.
3. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003; 4:441-7. (Pubitemid 36871763)
4. Brockbank JE, Schentag C, Rosen C, Gladman DD. Psoriatic arthritis (PsA) is common among patients with psoriasis and family medicine clinic attendees [abstract]. Arthritis Rheum 2001;44 Suppl:S94.
5. Reich K, Kruger K, Mossner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009;160:1040-7.
6. Espinoza LR, Zakraoui L, Espinoza CG, Gutierrez F, Jara LJ, Silveira LH, et al. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 1992;19: 872-7.
7. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al, for the Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50.
8. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64:1150-7.
9. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al, for the Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
10. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50: 2264-72.
11. Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006;65:1373-8.
12. Daunt AO, Cox NL, Robertson JC, Cawley MI. Indices of disease activity in psoriatic arthritis. J R Soc Med 1987;80: 556-8.
13. Kavanaugh A, Cassell S. The assessment of disease activity and outcomes in psoriatic arthritis. Clin Exp Rheumatol 2005;23 Suppl 39:S142-7.
14. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64 Suppl 2:ii49-54.
15. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64 Suppl 2:ii65-73.
16. Gladman DD, Cook RJ, Schentag C, Feletar M, Inman RI, Hitchon C, et al. The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada. J Rheumatol 2004; 31:1126-31.
17. Veale D, FitzGerald O. Psoriatic arthritis: "DIP or not DIP? That is the question." Br J Rheumatol 1992;31:430-1.
18. Helliwell PS. Therapies for dactylitis in psoriatic arthritis: a systematic review. J Rheumatol 2006;33:1439-41.
19. McQueen F, Lassere M, Bird P, Haavardsholm EA, Peterfy C, Conaghan PG, et al. Developing a magnetic resonance imaging scoring system for peripheral psoriatic arthritis. J Rheumatol 2007;34:859-61.
20. Scarpa R, Biondi Oriente C, Oriente P. The classification of psoriatic arthritis: what will happen in the future? J Am Acad Dermatol 1997;36:78-83.
21. Scarpa R, Soscia E, Peluso R, Atteno M, Manguso F, Del Puente A, et al. Nail and distal interphalangeal joint in psoriatic arthritis. J Rheumatol 2006;33:1315-9.
22. Tan AL, Benjamin M, Toumi H, Grainger AJ, Tanner SF, Emery P, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis: a high-resolution MRI and histological study. Rheumatology (Oxford) 2007;46:253-6.
23. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
24. Leeb BF, Andel I, Sautner J, Fassl C, Nothnagl T, Rintelen B. The Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients. Arthritis Rheum 2007;57:256-60.
25. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
26. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
27. Potter EM, McEwen C. Psoriatic arthritis: clinical features with particular reference to distal interphalangeal joint involvement. Br J Rheumatol 1992;31:646-7.
28. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA): an analysis of 220 patients. Q J Med 1987;62:127-41. (Pubitemid 17042878)
29. Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M, Wylie GL, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995;38:38-43.
30. Fransen J, van Riel PL. DAS remission cut points. Clin Exp Rheumatol 2006;24 Suppl 43:S29-32.
31. Ujfalussy I, Koo E. Measurement of disease activity in psoriatic arthritis: extended report. Z Rheumatol 2003;62:60-5.
32. Vander Cruyssen B, De Keyser F, Kruithof E, Mielants H, van den Bosch F. Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo. Ann Rheum Dis 2007;66:138-40.
33. Gladman DD, Mease PJ, Krueger G, van der Heidje DM, Antoni C, Helliwell PS, et al. Outcome measures in psoriatic arthritis. J Rheumatol 2005;32:2262-9.
34. Kavanaugh A, Ritchlin C, Boehncke WH. Quality indicators in psoriatic arthritis. Clin Exp Rheumatol 2007;25 Suppl 47: 98-101.